Lixisenatide (revision 1)
Old revision·00:25, 8 Oct 2024·ColdChainCleo
This is an old revision of this page, as it stood at 00:25, 8 Oct 2024, saved by ColdChainCleo with the summary start article on the compound. It may differ substantially from the current revision, and any error it contains may since have been corrected.
| Lixisenatide | |
|---|---|
| Class | GLP-1 receptor agonist |
| Origin | Exendin-4 derivative |
| Route | Subcutaneous, once daily |
| Outcome trial | ELIXA; neutral |
| Compound infobox · conventions | |
Lixisenatide is a GLP-1 receptor agonist derived from exendin-4, the same scaffold as exenatide, with a modified C-terminus. It is short-acting and given once daily.[1]
Its pharmacological profile emphasises postprandial glycaemic control through pronounced delay of gastric emptying, an effect that does not attenuate as it does with continuously present long-acting agonists.[2]
References
- ^ Pfeffer MA, Claggett B, Diaz R, et al. "Lixisenatide in patients with type 2 diabetes and acute coronary syndrome." New England Journal of Medicine 373(23):2247–2257 (2015). PMID 26630143.
- ^ Drucker DJ. "Mechanisms of action and therapeutic application of glucagon-like peptide-1." Cell Metabolism 27(4):740–756 (2018). PMID 29617641.
Categories: